Everolimus for the prevention of calcineurin-inhibitor-induced left ventricular hypertrophy in heart transplantatio

Phase 1

• Conditions: eft ventricular hypertrophy in heart transplantation; Left ventricular hypertrophy in heart transplantation; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12614000387628
• Lead Sponsor: St. Vincent`s Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Stable orthotopic heart transplant recipients at 3-months after heart transplantation and willingness to provide informed consent.

Exclusion Criteria

Hemodynamic instability at 10 weeks after transplantation, greater than 2 x 3A rejection or single 3B rejection, ongoing sepsis at 10 weeks after transplantation, ongoing wound dehiscence or infection at 10 weeks after transplantation, end-stage renal failure requiring dialysis at 10 weeks after transplantation, and contraindication to cardiovascular magnetic resonance scanning

Study & Design

• Study Type: Interventional
• Study Design: Not specified